About: Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 10 January 2019

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в березні 2019 (uk) article scientifique publié en 2019 (fr) artículu científicu espublizáu en xineru de 2019 (ast) im Januar 2019 veröffentlichter wissenschaftlicher Artikel (de) 2019 թվականի հունվարի 10-ին հրատարակված գիտական հոդված (hy) scientific article published on 10 January 2019 (en)
publication date	wds:Q64231015-77ECAA70-427A-4CF7-9627-BD37BDB57EB6
publication date	2019-01-10 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q64231015-A21BBD09-51DA-4EEC-A13C-62C9A74C8838
language of work or name	English
exact match	wds:Q64231015-A75EE85E-B8E4-483A-B681-58D3B376BD53
exact match	https://scigraph.springernature.com/pub.10.1007/s40744-018-0138-y
cites work	wds:Q64231015-03003B96-E063-42D9-9DE2-42D09E0B0F12 wds:Q64231015-196D153D-3455-4C5D-819B-CDBFE0AEB2CE wds:Q64231015-268EAEA1-5FAF-4412-BA95-E583045763EC wds:Q64231015-36046C94-1795-44C1-AEDB-6B7472D0910F wds:Q64231015-3BF61BC8-304E-49A3-8162-97B9976F3223 wds:Q64231015-59E31927-1463-404C-80C0-E2BCDAB395E1 wds:Q64231015-670BC3E6-65D1-4C76-B5EE-678511EEE7EA wds:Q64231015-6F3FD34C-E9FD-48D9-A412-23478C52A2B0 wds:Q64231015-7C373B6F-4DD4-4282-9B78-DCFE732AFA52 wds:Q64231015-84283F83-A83F-424C-A8C1-0BF075285B8C wds:Q64231015-89F09C74-F0C1-434F-961F-12E01077855E wds:Q64231015-90577F9F-4E16-4B59-8F7F-6ADCF5EBF6DD wds:Q64231015-92971F45-D9E4-4A4A-9125-7AE860E0BE18 wds:Q64231015-94FBD16D-1372-4627-A68D-0D32B92C5080 wds:Q64231015-98F84819-4E71-4AE7-9C23-6A6E8197B60A wds:Q64231015-A8230B29-5E4E-450B-9208-2F74B975766F wds:Q64231015-B3C29392-D50D-41CF-AB98-FDF523A61024 wds:Q64231015-BCCD57F0-A19E-40AF-8931-59FD632ED6C7 wds:Q64231015-D6070C93-7FDF-4C2E-AC7A-514293FF5386 wds:Q64231015-D699AD69-97CB-40EE-8D04-ED09632CB2AA
cites work	wd:Q28295371 Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumato Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA) Prevalence of rheumatoid arthritis in France: 2001 The role of interleukin 6 in the pathophysiology of rheumatoid arthritis The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting. Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study. [Medical and economic aspects of rheumatoid arthritis]
author name string	wds:Q64231015-06707AF3-5814-4EAE-9CF1-90994F12402A wds:Q64231015-2E149BBC-29F5-415E-B7B9-F2DF2CEB11A0 wds:Q64231015-3971F94F-183F-4E46-9B06-53BDBEE45921 wds:Q64231015-3D34D0EA-33C5-499A-8D2D-462828CFCA40 wds:Q64231015-4FA12C34-3024-4AC5-A1C7-103A8E080B3B wds:Q64231015-60854120-7890-4AFD-AB66-3BA0154F687E wds:Q64231015-6596D0B6-5F04-408D-B399-C202320DADC4 wds:Q64231015-884EC4A7-97DD-4E19-BFAF-B4A15411753D wds:Q64231015-989FE0A3-0BD4-4C2C-9B17-55EA2362E813 wds:Q64231015-CB0A65D7-638F-4F57-9BB5-BDAA806AB123 wds:Q64231015-DA0DA164-91B6-427C-B48C-8EF59D06BB25 wds:Q64231015-DC37C2B0-AFB7-4101-AAC7-EE03AF6FB65A wds:Q64231015-DFC9F736-6F51-4189-A2BA-F9BB6FD1348C wds:Q64231015-F53D3F44-4ACA-42AA-B478-C6D91E80D215
author name string	Jean-Hugues Salmon Jean-Paul Eschard René-Marc Flipo Eric Houvenagel Xavier Deprez Guy Baudens Marie-Hélène Guyot Isabelle Idier Laurent Marguerie David Pau Jean Darloy Nicolas Lecuyer Nicolas Segaud Samuel Gally
rdfs:label	Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study (en) Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study (nl)
skos:prefLabel	Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study (en) Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study (nl)
name	Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study (en) Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study (nl)
author	wds:Q64231015-80738BEB-2F83-46FF-A32F-79C7EEBC5151
author	Vincent Goeb
title	wds:Q64231015-A8E08E30-17E5-4A34-BE1E-5F99723A8374
title	Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study (en)
page(s)	wds:Q64231015-55DD6745-AEC4-4557-98F7-F35AE78D199A
page(s)	61-75
instance of	wds:Q64231015-E4AED2F1-1F92-43C3-9E47-BB8175EE35F2
instance of	scholarly article
main subject	wds:Q64231015-7DE2D38D-A93A-4514-86C5-AAEF9D76780E wds:Q64231015-F8A87129-D416-481A-8F1F-AB22F48A8DF7
main subject	rheumatoid arthritis tocilizumab

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 182 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software